title: Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.
abstract: Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant Staphylococcus aureus (MRSA). The population pharmacokinetics of arbekacin was investigated in the Japanese, using 353 patients infected with MRSA and 50 healthy or renally impaired volunteers. The age of the study population ranged from 8 to 95 years, and weight ranged from 10.8 to 107 kg. In total, 1,581 serum arbekacin concentrations were measured (primarily from routine patient care) and used to perform the present pharmacokinetic analysis. Drug concentration-time data were well described by a two-compartment open model. Factors influencing arbekacin pharmacokinetics were investigated using a nonlinear mixed-effect model analysis. The best-developed model showed that drug clearance (CL) was related to creatinine clearance (CL(CR)), age, and body weight (WT), as expressed by CL (liter/h) = 0.0319CL(CR) + (26.5/age) (CL(CR) < 80 ml/min) and CL (liter/h) = 0.0130 CL(CR) + 0.0342WT + (26.5/age) (CL(CR) >/= 80 ml/min). The volume of distribution for the central and peripheral compartments was different in healthy subjects and infected patients, and this difference was more pronounced among disease types. The elderly subjects (aged 80 years or over) exhibited, on average, a 19% greater volume for the central compartment. The volumes for the peripheral compartment were 50.6 liters in patients with pneumonia and 24.3 liters in patients with sepsis. The population pharmacokinetic parameters of arbekacin obtained here are useful for optimal use of this aminoglycoside in the treatment of MRSA-infected patients.
authors.affiliation: Department of Hospital Pharmacy, School of Medicine, Keio University, Tokyo 160-8582, Japan. tanigawa@sc.itc.keio.ac.jp
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tanigawara
authors.forename: Reiko
authors.initials: R
authors.lastname: Sato
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Morita
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Kaku
authors.forename: Naoki
authors.initials: N
authors.lastname: Aikawa
authors.forename: Kihachiro
authors.initials: K
authors.lastname: Shimizu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000617:Aminoglycosides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002648:Child; D003982:Dibekacin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D015233:Models, Statistical; D011153:Population; D015203:Reproducibility of Results; D018805:Sepsis / Q000378:metabolism / Q000382:microbiology; D013203:Staphylococcal Infections / Q000378:metabolism* / Q000382:microbiology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; C031986:arbekacin